Clinical trial NCT05688280: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
Official title: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. A Multicenter Phase 1b/2a Trial in Colorectal Cancer, Non-small Cell Lung Cancer, and Soft Tissue Sarcoma Patients
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Metastatic Solid Tumor
Colon Cancer
Nonsmall Cell Lung Cancer
Soft Tissue Sarcoma
Keywords: Cancer
Anti-cancer drug or therapy
Advanced solid tumors
Intratumoral injection
IP-001
Thermal ablation
Phase lb/lla
Melanoma
Soft tissue sarcoma
Tumor ablation
Systemic immune response
Interventional immuno-oncology
Interventional oncology
Abscopal effect
T-cell stimulation
Lead sponsor: Immunophotonics, Inc.
Sponsor class: INDUSTRY
First posted: 2023-01-18
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Open-label study with 3 Cohorts

* Cohort 1: 18 patients with Stage 3 or Stage 4 Colorectal Cancer (CRC)
* Cohort 2: 17 patients with Stage 3 or Stage 4 Non-Small Cell Lung Cancer (NSCLC)
* Cohort 3: 3 patients with Stage 3 or Stage 4 Soft Tissue Sarcoma (STS)

There will be 3 study periods: a Pretreatment Period, a Treatment Period, and a Follow-up Period.
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.

Detailed description: The therapeutic approach taken by this clinical trial may offer patients a therapeutic benefit after failure of standard chemotherapy and immunotherapy.

Patients giving written informed consent will undergo screening during the Pretreatment Period to determine eligibility for trial entry. The Pretreatment Period will include collection and recording of medical history, concomitant medications, baseline symptoms, previous therapies, and baseline assessments. The patient's baseline tumor burden will be recorded with radiological assessments, along with analyzing location and size of tumors to identify and characterize target tumor(s) that will be treated and/or followed during the clinical trial.

If confirmed eligible for the study, the patient will advance into the Treatment Period. During the Treatment Period, patients will receive a routine radiofrequency ablation (RFA), followed by an injection of investigational product (IP-001 for Injection) into the tumor. Patients can be treated every 6 weeks for up to 4 treatments with RFA + IP-001 for Injection.

A patient will move to the 6-month Follow-up Period when the patient has completed 4 treatment cycles or if the decision is made that no subsequent treatments will be administered. During the Follow-up Period, there will be a Follow-up Visit every 6 weeks for 5 visits, at disease progression, or prior to the start of a new antineoplastic treatment.

Eligibility criteria: Inclusion Criteria:

1. Stage 3 or Stage 4 CRC, NSCLC, or STS who have failed, are ineligible, refused, or become intolerant to at least first line (but no more than 4 lines) of systemic therapy
2. Life expectancy of \> 6 months. Only have lesions with the longest diameter of ≤ 5 cm.
3. Presence of at least one non-bone tumor lesion that is ablation-accessible, with a minimum size of 1.0 cm.
4. Measurable disease according to RECIST 1.1.
5. Age ≥ 18 years.
6. ECOG performance status 0-1.
7. Bone marrow function: neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L, hemoglobin ≥ 90 g/L.
8. Adequate hematological function defined by white blood cell count ≥ 2.5 × 109/L with absolute neutrophil count ≥ 1.5 × 109/L, and hemoglobin ≥ 9 g/dL (transfusions allowed on study).
9. Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range and aspartate transaminase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 × ULN for all patients, or for patients with documented metastatic disease to the liver and AST and ALT levels ≤ 5 × ULN. Patients with documented Gilbert disease are allowed if total bilirubin is less than 3 × ULN.
10. Adequate renal function defined by an estimated creatinine clearance ≥ 50 mL/min according to the Cockcroft-Gault formula (or local institutional standard method).
11. Men and women with childbearing potential agree to use effective contraception. Women of childbearing potential must have a negative pregnancy test (serum) before inclusion.

Exclusion Criteria:

1. Known allergic reaction to shellfish, crabs, crustaceans, or any trial components, used in trial treatment.
2. Malignant primary brain tumors or evidence of brain metastases or leptomeningeal disease.
3. Patients who have received chemotherapy, radiotherapy, immunotherapy, or concurrent or recent treatment with any other investigational agents within 21 days prior to treatment.
4. Patients who have not recovered to common terminology criteria for adverse events (CTCAE) Grade ≤ 1 from all side effects of prior therapies except for residual toxicities.
5. Patients with a history of malignancy, with the exception of non-melanoma skin cancers and in situ cancers.
6. Concomitant treatment with systemic corticosteroids (10 mg prednisolone or equivalent) or other immunosuppressive therapy.
7. Anti-coagulation therapies which cannot be stopped 24 hours prior to trial treatment.
8. Severe or uncontrolled cardiovascular disease (congestive heart failure New York Heart Association classification III or IV).
9. Documented HIV positive.
10. Active Hepatitis C or Hepatitis B Viral infection.

Primary outcomes:
measure: Safety and Tolerability
timeFrame: Up to 12 weeks
Secondary outcomes:
measure: Efficacy: Disease control according to Immune Response Evaluation Criteria in Solid Tumors for immune-based treatment (iRECIST) (iDC)
timeFrame: Up to 12 weeks
measure: Efficacy: Disease control according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (DC)
timeFrame: Up to 12 weeks
measure: Efficacy: Objective response according to iRECIST (iOR)
timeFrame: Up to 12 weeks
measure: Efficacy: Duration of response according to iRECIST (iDOR)
timeFrame: Up to 12 weeks
measure: Efficacy: Progression-free survival according to iRECIST (iPFS)
timeFrame: Up to 12 weeks
measure: Efficacy: Objective response according to RECIST 1.1 (OR)
timeFrame: Up to 12 weeks
measure: Efficacy: Duration of response according to RECIST 1.1 (DOR)
timeFrame: Up to 12 weeks
measure: Efficacy: Progression-free survival according to RECIST 1.1 (PFS)
timeFrame: Up to 12 weeks
measure: Efficacy: Time to response according to iRECIST 1.1 (iTTR)
timeFrame: Up to 12 weeks
measure: Efficacy: Time to response according to RECIST 1.1 (TTR)
timeFrame: Up to 12 weeks
measure: Efficacy: Disease-free survival (DFS)
timeFrame: Up to 12 weeks
measure: Efficacy: Overall survival (OS)
timeFrame: Up to 12 weeks
measure: Efficacy: OR of the injected lesions according to RECIST 1.1
timeFrame: Up to 12 weeks
measure: Efficacy: OR of the non-injected lesions according to RECIST 1.1
timeFrame: Up to 12 weeks
measure: Efficacy: iOR of the injected lesions according to iRECIST
timeFrame: Up to 12 weeks
measure: Efficacy: iOR of the non-injected lesions according to iRECIST
timeFrame: Up to 12 weeks
Other outcomes:
Locations:
city: Coral Gables
country: United States
facility: Miami Cardiac & Vascular Institute
state: Florida
city: Louisville
country: United States
facility: University of Louisville Physicians, PSC
state: Kentucky
city: Oklahoma City
country: United States
facility: Stephenson Cancer Center
state: Oklahoma
city: Bordeaux
country: France
facility: Institut Bergonie
city: Paris
country: France
facility: Hospitalier Pitie-Salpetriere
city: Suresnes
country: France
facility: Hôpital Foch
city: Villejuif
country: France
facility: Institut Gustave Roussy
city: Frankfurt
country: Germany
facility: Johann Wolfgang Goethe-Univresitat Frankfurt/Main
city: Heilbronn
country: Germany
facility: SLK-Kliniken Heilbronn GmbH
city: Munich
country: Germany
facility: Munchen Klinik Bogenhausen
city: Bellinzona
country: Switzerland
facility: IOSI Ospedale San Giovanni Bellinzona
city: Bern
country: Switzerland
facility: Inselspital Universitatsspital, Bern
city: Chur
country: Switzerland
facility: Kantonsspital Graubunden
city: St. Gallen
country: Switzerland
facility: Kantonsspital St. Gallen
city: London
country: United Kingdom
facility: University College London Hospitals
city: Oxford
country: United Kingdom
facility: Churchill Hospital
Study officials:
affiliation: Cantonal Hospital of St. Gallen
name: Markus Jorger, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Immunophotonics, Inc.
name: Diane Beatty, PhD
role: STUDY_DIRECTOR
References: